Pulmonary Arterial Hypertension: Meeting the Challenge of Early Diagnosis and Intervention

Jointly Provided by the University of Cincinnati and PlatformQ Health, Inc.

SUPPORT
This activity is supported by an educational grant provided by Actelion Pharmaceuticals US, Inc.

TUITION
Complimentary

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and PlatformQ Health Education, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity
The University of Cincinnati designates this Live Internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material
The University of Cincinnati designates this Enduring Material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.


DATE OF ORIGINAL RELEASE/EXPIRATION
Live Internet Activity
Wednesday, June 17, 2015, 3:00 PM – 4:00 PM EST  

Enduring Material
The enduring material will be available from June 17, 2015 – December 17, 2015.

ACTIVITY DESCRIPTION

Pulmonary arterial hypertension (PAH) is a progressive, multifactorial incurable disease. The most relevant pathogenic mechanism is characterized by intimal proliferation, median hypertrophy and the development of plexiform lesions. These changes ultimately lead to pulmonary vascular remodeling and increased pulmonary vascular resistance and elevated pulmonary arterial pressure, with increased right ventricular after-load. Because of its absent or vague symptomatology, patients with PAH are often diagnosed late in the course of the disease when pathologic changes are irreversible and prognosis is poor. Despite progress in understanding the cellular and genetic basis of PAH, the time to recognition has not improved over the past two decades and significant diagnostic care gaps exist. This critically underscores the importance of early recognition, rapid diagnosis and intervention with pharmacotherapy, including calcium channel blockers, phosphodiesterase inhibitors, prostacyclines and endothelin receptor antagonists to reduce morbidity and improve survival. Recent FDA approval of several new agents for PAH has added to the clinician challenge of keeping pace with rapid developments for a disease whose management can be complex. Clinicians must be educated on how best to intervene with appropriate pharmacotherapy to improve outcomes in patients with PAH.


LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:

Describe signs and symptoms associated with PAH and diagnostic tools that can provide an early and accurate diagnosis
Outline appropriate use of standard therapies to manage PAH
Discuss the clinical data supporting new and emerging PAH therapies, and their potential place in therapy

INTENDED AUDIENCE
This activity is intended for cardiologists, pulmonologists, primary care physicians, and other healthcare professionals who treat patients with pulmonary arterial hypertension (PAH).

ESTIMATED TIME TO COMPLETE ACTIVITY
This activity consists of one session, which should take approximately 1 hour to complete.


FORMAT
Internet

METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to http://www.cardiocarelive.com/. To receive credit, participants must (1) read the CME information, including the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. This activity consists of one session, which will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE & SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FINANCIAL DISCLOSURES

Presenters: Disclosures:
Fernando Torres, MD

Advisory Board: Gilead, Actelion, Bayer, Novartis, United Therapeutics
Consultant: Gilead, Actelion
Speaker’s Bureau: Gilead, Actelion, Bayer Grant
Recipient: Gilead, Bayer, Akaria

David B. Badesch, MD
Advisory Board: Actelion, Gilead, Pfizer, Bayer, United Therapeutics/Lung LLC
Consultant: Actelion, Gilead, Pfizer, Bayer, United Therapeutics/Lung LLC
Grant Recipient: Actelion, Gilead, Pfizer, Bayer, United Therapeutics/Lung LLC
   
University of Cincinnati
RELATIONSHIP(S)
Susan P. Tyler, MEd, CMP, CCMEP, Director
Has nothing to disclose
Rick Ricer, MD, CME Physician Reviewer
Has nothing to disclose
   
PlatformQ Health Education, LLC
RELATIONSHIP(S)
Carolyn Skowronski, PharmD, Medical Director
Shareholder: Merck
Karen Greb-Murphy, Program Manager
Nothing to disclose

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
The University of Cincinnati requires the presenter(s) to inform the audience when off-label or unapproved uses of drugs or devices are being discussed. Devices or drugs that are still undergoing clinical trials will be identified as such and will not be portrayed as standard, accepted therapy.

DISCLAIMERS (if applicable):
DISCLAIMERS (if applicable): The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the University of Cincinnati, CardioCareLive, PlatformQ Health or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.


CONTACT INFORMATION
Accreditation Support:
Please contact the University of Cincinnati Continuing Medical Education Department at uccme@uc.edu or call 513-558-7277.

Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.

 
CardioCareLive
Watch Connect online with thousands of your peers.
Connect Engage in real-time Q&A with top factuly.
Choose Learn about the latest treatment options.
Connect Earn AMA PRA
Category 1 Credits
™.